Novartis plans phase III study of hydroxychloroquine in hospitalized patients with COVID-19 disease April 20, 2020
Initiation of phase III RUXCOVID trial of ruxolitinib for COVID-19-associated cytokine storm April 20, 2020
FDA approves Tukysa for advanced, unresectable or metastatic HER2-positive breast cancer April 20, 2020
FDA clears anti-Claudin 18.2 antibody TST-001 to enter clinical trials for metastatic solid tumors April 20, 2020
Pemazyre approved in U.S. for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements April 20, 2020
RSS